+++ ₿₿ +++ Ripple +22% in den letzten 24 Stunden im Plus. Jetzt XRP handeln!** +++ ₿₿ +++-w-
15.12.2020 13:35:00

Could Regeneron Pharmaceuticals Be a Millionaire-Maker Stock?

With all the recent focus on COVID-19 vaccines and the successes of a new gene-based approach to developing drugs, it's understandable that investors might lose sight of companies that led earlier innovations in medicine. Monoclonal antibodies may sound like a recent innovation, but the first treatment using the technology was actually approved in 1986 -- the same year Top Gun led the box office. Regeneron (NASDAQ: REGN) -- an early pioneer in the field -- has delivered 1,530% returns to shareholders over the past decade. Unlike many biotechs with recently rising stock prices, it has been consistently growing sales and pumping out profits too. Can the company continue to deliver growth and be a millionaire-maker for investors from here?Image source: Getty ImagesTwo proteins -- antibodies and antigens -- are key to explaining how the immune system can be harnessed to fight disease. Antibodies circulate throughout the body looking for antigens to stick to. Once the two bind, the antibodies then call on other mechanisms of the immune system to destroy the cells with the antigens. That process is what scientists use to target cancer and other diseases with engineered antibodies.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"